What is the key clinical finding from Merck and Moderna's melanoma vaccine trial?

Merck and Moderna reported that their personalized mRNA cancer vaccine, combined with Keytruda, helped prevent the return and spread of melanoma in a large trial involving over 1,000 patients who had surgically removed localized tumors but were at high risk of recurrence.

How does the Merck-Moderna melanoma vaccine work differently from traditional cancer treatments like chemotherapy or standard immunotherapy?

Unlike chemotherapy—which kills both healthy and cancerous cells—or general immunotherapy—which broadly activates the immune system—the personalized cancer vaccine trains the immune system to specifically target mutations found only on a person's tumor, using a customized mRNA vaccine alongside Keytruda infusions.

Moderna, Merck Breakthrough Could Usher in Wave of Cancer Vaccines

Aug 19, 2026

Moderna and Merck reported positive Phase III trial results for a personalized mRNA melanoma vaccine, cutting recurrence risk by half. This breakthrough validates mRNA technology for oncology, with further trials planned for lung, bladder, and pancreatic cancers.

reuters

2026-03-10

March 10 Business Watch: Syngenta ends paraquat production; Moderna settles lipid patent case

2026-04-24

CureVac sues Moderna for patent infringement over COVID-19 vaccines

2026-08-19

Moderna shares surge as melanoma vaccine with Merck succeeds in large trial

2026-08-19

Moderna, Merck Breakthrough Could Usher in Wave of Cancer Vaccines

2026-08-19

Asian Stocks to Gain as US Treasury Supports Bonds: Markets Wrap